Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells
Margit Rosner1, Nicol Siegel, Christiane Fuchs
1Medical Genetics, Medical University Vienna, Vienna, Austria.
Nature Protocols
|June 12, 2010
Summary
We developed a simple 72-hour protocol for RNA interference (RNAi) to achieve prolonged gene silencing in human amniotic fluid stem cells (hAFSCs). This method is efficient and reproducible across various cell types.
Area of Science:
- Stem cell biology
- Molecular biology
- Gene regulation
Background:
- Human amniotic fluid stem cells (hAFSCs) offer significant potential for regenerative medicine due to their multipotency and safety profile.
- RNA interference (RNAi) is crucial for elucidating gene function and advancing tissue engineering applications.
- Existing methods for gene manipulation in hAFSCs are limited.
Purpose of the Study:
- To establish a rapid and effective protocol for gene knockdown in hAFSCs using small interfering RNA (siRNA).
- To demonstrate the feasibility of prolonged gene silencing in hAFSCs.
- To assess the broad applicability of the RNAi protocol across diverse cell lines.
Main Methods:
- A 72-hour lipid-based forward transfection protocol for siRNA delivery was optimized for hAFSCs.
- Gene knockdown efficiency and duration were evaluated.
- The protocol's efficacy was tested in multiple human cell types, including primary fibroblasts and cancer cell lines.
Main Results:
- The protocol achieved efficient, functional, and reproducible gene knockdown in hAFSCs.
- Sustained gene silencing was observed for approximately two weeks.
- Successful gene silencing was demonstrated in fibroblasts, cervical adenocarcinoma cells, embryonic kidney cells, endometrial stromal cells, and leukemia cells.
Conclusions:
- This study presents the first RNAi approach for sustained gene knockdown in hAFSCs.
- The developed protocol is straightforward, rapid, and applicable to a wide range of human cell types.
- This method facilitates functional genomics studies and holds promise for therapeutic applications in tissue engineering.

